Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 16 SEPTEMBER 2026 ASX RELEASE AMPLIA PRESENTS AT E&P HEALTHCARE CONFERENCE 2026 Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), is pleased to announce that CEO and Managing Director Dr Chris Burns will be presenting at the E&P Healthcare conference in Sydney, today. A copy of the presentation is attached. This ASX announcement was approved and authorised for release by the Managing Director of Amplia Therapeutics Company Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Investor Contact: Hannah Howlett, Titch Comms Hannah@titchcomms.com.au +61 450 648 064 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane® ) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year. A new trial, exploring the combination of narmafotinib with next-generation kRAS G12C inhibitor olomorasib in second-line NSCLC, is planned to start late 2026. 1 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF S E P T E M B E R 2 0 2 6 Targeting pancreatic cancer and beyond This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 Jun 2026. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below. Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia’s most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation. Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance. Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia’s actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company’s good faith assumptions as to the financial market, regulatory and other relevant environments that will exist and affect Amplia’s business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based. Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data. Financial Information: This Presentation contains historical financial information based on the Company’s results for the 12 month period ending 30 Jun 2026 and management accounts to 30 Jun 2026. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding. Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement. Disclaimer 2 Exciting data from ACCENT Trial Superior to chemo alone Phase 2b/3 registration enabling FDA Orphan drug & Fast track designation Lead program PRROSE Trial HGSOC patients | ANZGOG High FAK expression 1 in 5 don’t respond to chemo Emerging opportunity 80+ kRAS drugs in development Preclinical ATX models show narmafotinib can improve kRAS inhibitors The FAK Opportunity A large and unmet clinical need exists in cancers where FAK contributes to disease Pancreatic Cancer Ovarian Cancer kRAS Combinations US$2.5b market1 US$3.9b market2 US$32b lung cancer market3 US$19b CRC market4 3 1. 2025 7MM’s, Clarivate/ Nature Reviews Drug Discovery 25, 416-417 (2026); 2. 2025 7MM’s, Clarivate/ Nature Reviews Drug Discovery 25, 674-675 (2026); 3. Global markets, Fortune Business Insights Targeting fibrosis and resistance NARMAFOTINIB Chemotherapy Narmafotinib breaks down fibrosis surrounding the tumour, and blocks survival and resistance pathways in cancer cells FAK drives a dense fibrous matrix that surrounds the tumour and creates a barrier for chemotherapy Narmafotinib acts to reduce the fibrous tissue thus allowing chemotherapy and other treatments to penetrate Chemotherapy can now kill cancer cells and narmafotinib blocks resistance processes 4 5 ACCENT Trial in pancreatic cancer Excellent tolerability and responses observed Narmafotinib plus standard-of-care chemotherapy Newly diagnosed patients Metastatic disease 64 patients at top dose narmafotinib Phase 1b/2a clinical trial in Australia and South Korea Narmafotinib Chemotherapy Taken orally in days preceding chemotherapy Three infusions every four weeks ACCENT Pancreatic Cancer Trial 6 7.8% Complete response rate Superior to chemo alone (~0.2%) 70% Disease control rate Chemo alone - 50% 11.1 Median overall survival Chemo alone - 8.5 mo months No Extra Burden Safety & tolerability Over chemo alone ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / Abraxane in first-line advanced pancreatic cancer months 7 5 CR’s and 1 pCR from 64 pts 8% CR, 28% PR, 34% SD mPFS 7.7 mos v 5.5 mos (MPACT) Main narma TEAEs: nausea, vomiting, diarrhoea ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine / abraxane in first-line advanced pancreatic cancer 8 Deep and sustained tumour shrinkage OS related to Response White circles indicate patients alive at March review Underway Final planning Final planning ACCENT registration pathway ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 Daily dosing at two dose levels Gemcitabine + Abraxane combination 12 patients - 2 cohorts 3–4 Australian sites Safety, tolerability, PK + efficacy Biomarker endpoints Timeline First patient dosing Sept 2026 Safety and PK review complete Q1 27 Builds on ACCENT Mini data to compare the two daily dosing levels head-to-head to identify the optimal dose of narmafotinib ahead of the Phase 3 study Following Project Optimus* principles Pivotal registrational study conducted with the dose selected from P2b Designed to support FDA submission for narmafotinib approval in pancreatic cancer A three-part registration pathway designed around FDA feedback FDA meeting planned Q2 27 Start 2H 27 9 Timeline * Project Optimus: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus The Pancreatic Cancer treatment landscape New developments changing treatment journey Nature Reviews Drug Discovery 2026, 25, 416-417 (Clarivate) Market Size (7 MM) Chemotherapy predicted to remain a significant component of treatment paradigm FOLFIRINOX and gemcitabine+Abraxane are main chemotherapy options Growing awareness that gemcitabine+Abraxane combination has similar efficacy with improved tolerability US$6,500-7,500/month Recently approved NALIRIFOX (approved in US) offers good efficacy with reduced toxicity US$13,610/month kRAS/RAS inhibitors most exciting of new treatment options Daraxonrasib US approval for second-line advanced PDAC in August 10 11 kRAS Inhibitors An exciting new class of anti-cancer therapies - ideally suited for FAK inhibitor combination Clinical studies demonstrating good activity 80+ kRAS drugs now in clinical development Across pancreatic cancer, NSCLC, colorectal cancer and others Resistance and tolerability significantly limits long term treatment Type % kRAS Prevalence kRAS mutations prevalent in cancer Significant cancer driver in multiple indications 12 13 Significant competition in development Amgen BMS Genfleet InventisBio Bridge Bio BI D3 BIO Merck Lilly Roche JNJ RevMed Astellas AZ Incyte Hansoh RevMed JacoBio Innovent Tyligand Ranok Frontier Genhouse Lilly Quanta Astellas Alterome Bayer Astellas AZ BridgeBio Amgen Lilly Chugai Erasca RevMed RevMed Verastem InventisBio HuyaBio Qilu Roche Pfizer Kestrel Combinations critical to development strategy Phase 1 Phase 2 Phase 3 Approved G12C G12D pan SJ Pharma 14 The Opportunity Ahead Combinations critical to development strategy Narmafotinib and kRAS inhibition Overcoming acquired resistance to kRAS inhibitors FAK signaling is an escape mechanism to blockade of RAS pathway Growing evidence for clinical benefit of FAK + kRAS inhibition Approval of defactinib + avutometinib (Co-Pack) in kRAS mutant LGSOC - Verastem Promising early clinical data from Inxmed (Lancet Resp. Med. 2026) Preclinical studies showing improved efficacy in combination FAK Pathways invoked Akt/mTOR wnt Hippo RhoA DDR ... 15 Drug Trial Setting mPFS mOS ORR Adagrasib KRYSTAL-12 Phase 3 2L+ NSCLC 5.5 mos Immature 31.9% Sotorasib CodeBreaK 200 Phase 3 2L+ NSCLC 5.6 mos 10.6 mos N/A Olomorasib LOXO-RAS- 20001 Phase 1/2 2L NSCLC 8.1 mos NR 41% Lilly Collaboration - Background Enhancing efficacy for next-generation kRAS G12C inhibitor FDA-approved G12C targeted drugs - first generation Adagrasib (BMS); Sotorasib (Amgen) Clinical data: Promising efficacy signals resulted in accelerated approvals Tolerability issues have limited market penetration Olomorasib - a next-generation kRAS G12C inhibitor Improved potency and selectivity Promising P1/2 data has supported further development Currently undergoing two global Phase 3 studies in 1L NSCLC 16 Olomorasib (100 mg, BID) Previously treated KRAS G12C-mutant advanced or metastatic NSCLC Phase 1b/2b study Dose escalation of narmafotinib with standard dose olomorasib (approx. 20 pts) Randomised 2-dose comparison – following Project Optimus guidelines (approx. 40 pts.) Australian and US sites Contractual Amplia to sponsor and fund study out of existing funds Lilly to supply olomorasib in-kind for use in the study Resulting data to be shared between both parties Non-exclusive Narmafotinib (200 mg, QD) Narmafotinib (400 mg, QD) Narmafotinib (600 mg, QD) Olomorasib (100 mg, BID) Narmafotinib (Dose 1, QD) Narmafotinib (Dose 2, QD) Olomorasib (100 mg, BID) Lilly Collaboration - Detail Enhancing efficacy for next-generation kRAS G12C inhibitor vs. Phase 1b Phase 2b 17 Lilly Collaboration Important validation of the potential of our science Eli Lilly and Co. Market Cap US$1.1 T Marketed oncology drugs Verzenio (abemaciclib) Jaypirca (pirtobrutinib) Retevmo (selpercatinib) A deep pipeline of small molecules drugs, radiopharmaceuticals and biologicals 3 kRAS inhibitors in development (G12C, G12D, and pan-kRAS) Lilly Oncology Pipeline kRAS inhibitors 18 19 PRROSE Trial in ovarian cancer Building on promising preclinical and literature data 70% of patients are diagnosed at advanced stage where 5-year survival is 20% 20% of patients will be resistant or develop resistance during initial treatment Ovarian Cancer ~50% of an ovarian tumour is fibrotic - a key driver of drug resistance 20 ~20 Patients HGSOC poor chemo response Treatment Narmafotinib + Carboplatin / paclitaxel Surgery interval debulking surgical resection Endpoints Safety, surgical eligibility tissue + biomarkers TRIAL PARTNER ANZGOG Australia New Zealand Gynaecological Oncology Group — international cooperative trials network spanning major hospitals across Australia and New Zealand PRROSE Trial The study is an investigator-initiated clinical trial led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG 21 2026 2027 2028 Development Timeline 2029 ACCENT ACCENT-mini ACCENT-reg PRROSE FDA Meeting FDA Meeting safety data 22 2026 2027 2028 Development Timeline 2029 ACCENT ACCENT-mini ACCENT-reg PRROSE Olomorasib combination KRASi combination 2 FDA Meeting FDA Meeting safety data 23 2026 2027 2028 Development Timeline 2029 ACCENT ACCENT-mini ACCENT-reg PRROSE Olomorasib combination KRASi combination 2 KRASi arm FDA Meeting FDA Meeting safety data 24 12 month share price chart ASX:ATX | OTCQB:INNMF Corporate Summary Share price (15-Sep-2026) A$0.12 Shares on issue 513.3M Market cap (15-Sep-2026) A$61.60M Cash at hand (30-Jun-2026) A$24.0M Substantial Shareholders Platinum Investment Management Ltd Acorn Capital Ltd Blueflag Holdings Pty Ltd Pengana Capital Group 25 Rhiannon Jones PhD GAICD COO MBBS FRACP CMO Jason Lickliter BCom MA CA GIA(Cert) CFO Warwick Tong MB ChB MPP GAICD Director Chris Burns PhD GAICD FAHMS CEO and MD Brett Carter BSc MBA GAICD Director Robert Peach PhD Director Jane Bell AM LLB LLM (Lond) FAICD Chair BOARD Hamish George SENIOR MANAGEMENT Jonathan Barlow LLB BSc GDipBA GAICD Head of BD 26 Board and Management World-class expertise Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF info@ampliatx.com ampliatx.com Chris Burns CEO and MD chris@ampliatx.com​ PhD GAICD FAHMS Thank You